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Abstract: The synthesis, characterization, and in vitro antiparasitic and anticancer activity evaluation
of new conjugates containing two and three dinuclear trithiolato-bridged ruthenium(II)-arene units
are presented. Antiparasitic activity was evaluated using transgenic Toxoplasma gondii tachyzoites
constitutively expressing β-galactosidase grown in human foreskin fibroblasts (HFF). The compounds
inhibited T. gondii proliferation with IC50 values ranging from 90 to 539 nM, and seven derivatives
displayed IC50 values lower than the reference compound pyrimethamine, which is currently used for
treatment of toxoplasmosis. Overall, compound flexibility and size impacted on the anti-Toxoplasma
activity. The anticancer activity of 14 compounds was assessed against cancer cell lines A2780,
A2780cisR (human ovarian cisplatin sensitive and resistant), A24, (D-)A24cisPt8.0 (human lung
adenocarcinoma cells wild type and cisPt resistant subline). The compounds displayed IC50 values
ranging from 23 to 650 nM. In A2780cisR, A24 and (D-)A24cisPt8.0 cells, all compounds were
considerably more cytotoxic than cisplatin, with IC50 values lower by two orders of magnitude.
Irrespective of the nature of the connectors (alkyl/aryl) or the numbers of the di-ruthenium units
(two/three), ester conjugates 6–10 and 20 exhibited similar antiproliferative profiles, and were
more cytotoxic than amide analogues 11–14, 23, and 24. Polynuclear conjugates with multiple
trithiolato-bridged di-ruthenium(II)-arene moieties deserve further investigation.
Keywords: bioactive organometallics; polynuclear ruthenium compounds; antiparasitic; anticancer
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1. Introduction
The recent high interest in the development of therapeutic transition metal complexes
is in part driven by the clinical success of the platinum(II) anticancer drug, cisplatin (cis-
diamminedichloroplatinum(II)). Cisplatin has become an important component in chemotherapy
regimens for the treatment of ovarian, testicular, lung and bladder cancers, as well as lymphomas,
myelomas and melanomas [1–4]. The use of known platinum drugs is limited by the incidence of
intrinsic or acquired drug resistance [5–8] and by their high toxicity and severe side-effects [9–12].
Currently, there are six platinum drugs with marketing approval in various regions throughout the
world: cisplatin, carboplatin, oxaliplatin, nedaplatin, lobaplatin, and heptaplatin. Important research
efforts are directed towards the development of other platinum(II) or (IV)-based drugs that overcome
these drawbacks [13–17]. Over the last 40 years, numerous platinum drugs have entered clinical trials,
but only two (carboplatin and oxaliplatin) have gained international marketing approval, and another
four have obtained regulatory approval in individual countries: heptaplatin (Korea), lobaplatin (China),
miriplatin and nedaplatin (Japan) [10].
Along with platinum, other transition metals including gold, titanium, rhodium, iridium,
ruthenium and osmium, as well as essential metals such as iron, copper, zinc and cobalt, inspired the
development of numerous organometallic compounds as potential anticancer candidates due to
their variable coordination modes, redox activity and reactivity towards biomolecules [18–23].
Parallel studies were focused on the identification of other pharmacological applications of metalorganic
compounds, e.g., diagnostic tools as biomolecular and cellular probes [24–26] or antibacterial, antifungal,
and antiparasitic therapeutics [27–33].
Among the numerous inorganic and organometallic compounds presenting anticancer properties,
ruthenium(II) and (III) complexes were identified as some of the most promising alternatives for the
replacement of platinum drugs [23,34–40]. For these ruthenium compounds, the oxidation state of
the ruthenium atom, their solubility and stability in physiological media, greatly influence their
activity against cancer cells. Three ruthenium(III) metal based complexes, NAMI-A ((ImH)[trans-
RuCl4(dmso-S)(Im)], Im = imidazole) and KP1019/1339 (KP1019 = (IndH)[trans-RuCl4(Ind)2], Ind = indazole;
KP1339 = Na[trans-RuCl4(Ind)2]), were subjected to clinical tests [41–44], while the most advanced
ruthenium(II) complex is TLD1433 ((Ru(4,4′-dimethyl-2,2′-bipyridine)2(2-(2′,2′′:5′′,2′′′-terthiophene)-
imidazo [4,5-f])]Cl2), a photosensitizer that has recently entered clinical trials for non-muscle
invasive bladder cancer [45–47]. Several ruthenium(II)-arene compounds including RAPTA-C
([Ru(II)(η6- p-MeC6H4Pri)(PTA)Cl2], PTA = 1,3,5-triaza-7-phosphatricyclo-[3.3.1]decane) and RM175
([Ru(II)(η6-biphenyl)(en)(PF6)], en = ethylenediamine) (Figure 1) were submitted to advanced in vitro
and in vivo studies [48–52].
This opened the door for the development of a myriad of organometallic complexes bearing the
half-sandwich ruthenium(II)-arene scaffold [53,54]. Among those, symmetric and mixed cationic trithiolato-
bridged dinuclear ruthenium(II)-arene compounds of general formula [(η6-p-MeC6H4Pri)2Ru2(µ2-
SR)3]+ [55,56] and, respectively, [(η6-p-MeC6H4Pri)2Ru2(µ2-SR1)(µ2-SR2)2]+ [57] (Figure 1) have shown high
cytotoxicity against human cancer cells (IC50 values as low as 30 nM against A2780 human ovarian cancer
cells and the cisplatin-resistant variant A2780cisR) [58]. This encouraged the synthesis and evaluation of
various libraries of complexes based on the trithiolato-bridged di-ruthenium scaffold in the pursuit
of improved anticancer properties [55,58,59], but also opened the door for a broader scope, with the
assessment of alternative biological applications such as antiparasitic activity [60–62].
Several symmetric complexes [(η6-p-MeC6H4Pri)2Ru2(µ2-S-p-C6H4R)3]+ with R = p-Me (A),
p-But (B), p-OH (C) (Figure 1) presenting interesting in vitro cytotoxicity against cancer cells (IC50 values
of 30 nM against A2780 and A2780cisR cells for B) were also assessed in mice [63–65]. Mixed complexes
(as D, [(η6-p-MeC6H4Pri)2Ru2(µ2-SR1)(µ2-SR2)2]+ with R1 = CH2-C6H4-p-But, R2 = C6H4-p-OH,
X = Cl-, Figure 1) also exhibited cytotoxicity against A2780 and A2780cisR cells in the nanomolar
range [57].
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Figure 1. Structures of the ruthenium(II)-arene complexes RAPTA-C and RM175, of selected symmetric
and mixed trithiolato-bridged ruthenium(II)-arene complexes, and of the trinuclear platinum compound
BBR 3464.
Despite their unusual high potency, this class of ruthenium complexes was not selective for cancer
cells and displayed a low water solubility [58]. Unlike other Ru(II)-arene complexes presenting labile
chlorine or carboxylate ligands, they were stable in the presence of water, amino acids and DNA [58]
and interacted weakly in a noncovalent manner with proteins, including HSA (human serum albumin),
Tf (transferrin), Cytc (cytochrome c), Ub (ubiquitin) and Mb (myoglobin) [58]. Only the oxidation
of cysteine (Cys) and glutathione (GSH) to form cystine and GSSG, respectively, was observed in
the presence of this type of complexes [55,58], but no correlation between the in vitro cytotoxicity
and the catalytic activity on the glutathione oxidation was observed [55,58]. Inductively coupled
plasma mass spectrometry (ICP-MS) experiments proved that complexes A and B specifically target
the mitochondrion in A2780 ovarian cancer cells, with up to 97% of the Ru content found in the
mitochondrial fraction [61].
Recently it was shown that some cationic trithiolato-bridged dinuclear ruthenium(II)-arene
compounds display interesting in vitro activities against two apicomplexan parasites Toxoplasma
gondii [60] and Neospora caninum [61], which cause abortions and fetal malformations in humans
(T. gondii) and animals (T. gondii and N. caninum), and against Trypanosoma brucei [62], the causative
agent of African sleeping sickness. In addition, several compounds derived from a library of coumarin
conjugates of trithiolato di-ruthenium complexes showed promising activity against T. gondii [66].
Thus, A and B inhibited T. gondii proliferation with IC50 values of 34 and 62 nM, respectively, and they
did not affect HFF host cells at dosages of 200 µM or above, resulting in high selectivity indices.
Transmission electron microscopy (TEM) detected ultrastructural alterations in the matrix of the parasite
mitochondria at the early stages of treatment with D (X− = BF4−), followed by a more pronounced
destruction of tachyzoites. However, compounds A, B, or D applied at 250 nM did not act in a
parasiticidal manner. Furthermore, complexes A, B, and D also inhibited N. caninum proliferation
with low IC50 values of 15, 5 and 1 nM, respectively. [60–62] TEM also indicated that the parasite
mitochondrion was the primary target, but parasiticidal activity was also not detected. Complexes A,
B, and D applied orally in a neosporosis mouse model did not reduce parasite load in the central
nervous system. These encouraging results stimulated us to develop a new library of complexes based
on the trithiolato-bridged di-ruthenium scaffold and evaluate them as antiparasitic agents.
Polynuclear compounds are a relatively new and successful approach in metal-based cancer
chemotherapy as exemplified by the trinuclear platinum compound BBR 3464 [{trans-PtCl(NH3)2}-
µ-{trans-Pt(NH3)2(H2N(CH2)6NH2)2}][NO3]4, (Figure 1) which was evaluated in clinical trials [67–70].
BBR 3464 exhibited interesting biological activity and a potentially different mode of action compared to
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mononuclear cisplatin. The introduction of two additional metal fragments to the platinum scaffold led
to a higher activity in cisplatin-resistant cell lines and tumour models for the trinuclear complex [71–75].
The high cytotoxicity of the polynuclear platinum compound against cisplatin resistant cells was
attributed to the different type of DNA-adducts formed compared to those of cisplatin, but also to the
increased number of platinum moieties [71,76–78].
Despite BBR 3464 failing clinical trials due to limited response in patients [68,79], the polynuclear
strategy was considered promising and an increased interest in the development of other compounds
with two or more metal centres emerged. Various homo-polynuclear ruthenium, osmium and gold
complexes were developed, in the quest of anticancer chemotherapeutics [78,80–82]. Some compounds
were shown to exert their anticancer activity by different modes of action compared to established drugs,
including enzyme inhibition or crosslinking of DNA or proteins [78,80,81]. Numerous polynuclear
half-sandwich metal-arene (ruthenium, osmium, rhodium, iridium) complexes have been investigated
for their anticancer, antibacterial or antiparasitic properties [83–97].
In some reports, the biological activity of polynuclear compounds was compared to that of the
corresponding mononuclear analogues [88,92,95,98]. However, no general trend can be determined
regarding a direct correlation between the number of the organometallic units and the measured
biological properties. The results remained strongly specific to the various types of compounds and
each case should be considered individually. Apart the number of the metal centres, other parameters
play an important role with regard to the stability and efficiency of the polynuclear complexes: (i) the
nature of the metal, (ii) the type of ligands and the coordination mode (mono- or bidentate), (iii) the
length, stereochemistry and steric hindrance of the linking units, (iv) the hydrophobicity and other
physico-chemical properties such as the total size and charge.
Numerous homo-polynuclear Ru(II)-arene complexes with various type of connections disposed
at the level of the arene or on leg ligands were previously evaluated. For example, the concept of
polynuclearity was applied to RAPTA complexes by connecting two ruthenium(II) metalorganic units
at the level of the arene ligand (Figure 2) [92,93]. Flexible alkyl or polyethylene glycol (PEG) diamines,
as well as 1,2-diphenylethylenediamines with controlled configuration, were chosen as linkers [92,93].
In this case, dinuclear compounds presented increased cytotoxicity compared to the corresponding
mononuclear derivatives when assessed in A2780, A2780cisR and HEK293 (human embryonic kidney)
cells, but no important selectivity towards cancer cells could be observed. The conformation had a
strong impact on the cytotoxicity and the compounds were shown to crosslink the two dominant
RAPTA-C histone sites on the acidic patch of the NCP (Nucleosome Core Particle) [93]. This type
of dinuclear compounds induced aberrant chromatin condensation, due to intra-nucleosomal and
inter-nucleosomal cross-linking [93].
Another example is that of a series of structurally related mono- (G), di- (H) and trinuclear
(I) compounds containing {(η6-p-MeC6H4Pri)RuCl[3-oxo-κO)-2-methyl-4-pyridinonato-κO4]} units
(Figure 2) evaluated for cytotoxicity against various cancer cells [96–98]. The units in the dinuclear
compounds H were linked via flexible alkyl chains of varying lengths and a correlation between
the linker size, lipophilicity, and cytotoxicity was observed. Whilst the mononuclear G was inactive
against A2780 cells at concentrations up to 50 µM [99], the dinuclear compound bearing the longest
chain (n = 12) exhibited an IC50 value of <2 µM [96]. In addition, the dinuclear compound bearing the
longest spacer (n = 12) displayed a different mode of binding to the rest of the series and could form a
high degree of DNA–protein and DNA duplex crosslinking. The extent of DNA–protein crosslinks
was shown to be dependent on the spacer length [97,100]. The number of metal centres was found
to be important, with the dinuclear compound being more active than the analogous mono- (G) and
trinuclear (I) compounds.
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The compounds used in this study not only have a higher charge, but also an important
augmentation in size/molecular weight compared to each individual component. Various structural
modifications were investigated. In the case of the conjugates with two units, the type of the bonding
(ester vs. amide) as well as the nature and length of the linker were systematically varied. In the
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case of the conjugates containing three units, two topologies were considered: a tripodal star-shape
and a linear ‘beads-on-a-string’ arrangement. The nature of the central moiety was also customized
(see Supplementary Figure S1 for a schematic representation of the compounds).
Trithiolato-bridged dinuclear ruthenium(II)-arene compounds are stable, which allows the
synthesis of more sophisticated molecules by applying ‘chemistry on the complex’. First investigations
in this direction were reported in studies on conjugates with peptides [101], the anticancer drug
chlorambucil [102] and the fluorophore coumarin [66] designed to improve the water solubility and to
promote the anticancer and antiparasitic activities. In general, the synthesis of both the symmetric and
mixed trithiolato complexes is straightforward and efficient [57,66].
The mixed intermediate compounds 3–5 containing one di-ruthenium unit and one or two
hydroxy or amino groups were synthesized following the reactions presented in Scheme 1 by adapting
previously described procedures [57,66]. A two-step reaction pathway was used, starting from
the [Ru(η6-p-MeC6H4Pri)Cl]2Cl2 dimer [103]. In the first step, the reaction of two equivalents of
(4-(tert-butyl)phenyl)methanethiol and, respectively, 4-mercaptophenol with the ruthenium dimer in
EtOH (0 ◦C), under inert atmosphere (N2) afforded the symmetric neutral dithiolato intermediates 1
and 2 isolated with 91% yield each. The reactivity of the thiols strongly influences the recovery of the
dithioato intermediates, being easily controlled stoichiometrically for 1 when a benzyl thiol was used,
but not for 2, based on a phenyl thiol, for which the respective monothiolato and trithiolato compounds
were also formed. The dithiolato intermediates 1 and 2 were further reacted with a third thiol in excess
in refluxing EtOH under inert atmosphere (N2) to obtain the mixed complexes 3–5 isolated in good
yields (82%, 84%, and 96%, respectively).
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Scheme 1. Synthesis of the mixed trithiolato-bridged ruthenium(II)-p-cymene intermediates 3–5.
The diester and diamide conjugates containing two di-ruthenium units were obtained by reacting
intermediates 3 and 4 with suitably difunctional compounds bearing two acyl chloride or carboxylic
acid groups using appropriate reaction conditions (Schemes 2–4). With few exceptions, the syntheses per
se did not impose particular issues and the conversions were generally good. Nevertheless, the isolation
of the pure compounds proved in some cases less straightforward (yields ranged from 7% to 50%).
These purification issues were translated in some cases in poor yields f isol t d pure dicationic and
tricati nic conjugates (see full details in Supporting information). However, the quantities of the
isolated products were sufficient f r the bi logical activity screening.
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The diester co jugates 6–10, presenting alkyl linkers of different lengths (n = 2–6) wer obtained
with a yield ranging from 7% to 50% by reacting two equivalents of the hydroxy di-ruthenium
intermediate 3 with various commercially available bis-acyl chloride compounds in basic conditions
(TEA, triethylamine), at low temperature (0 ◦ ) under inert atmosphere (N2) (Scheme 3).
The diest r conjugates from th i of 3 with oxalyl chloride (n = 0) and malonyl chloride
(n = 1) could not b isolat d du t radation of t e acyl chlorid r age ts in the used reaction
conditions. For example, the reactio f ith malonyl chlorid led to the isolation of the acetyl ester
side product.
Similar reaction conditions were used for the synthesis of the alkyl dia ide conjugates 11, 12,
and 14 isol ted in 44%, 37%, and 34% yield, respectively. Two equivalents of amino intermediate 4
were reacted w th the correspon ing bis-acyl chloride compounds (n = 0, 4, and 6) in basic conditions
(TEA) at low temperature (0 ◦C) under inert at osphere. Diamide conjugate 13 (n = 5) was obtained
with 43% yield using heptanedioic acid, in the presence of HOBt (1-hydroxybenzotriazole) and EDCI
(N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride) as coupling agents and DIPEA
(N,N-diisopropylethylamine) as base (Scheme 3, full experimental details are given in Supporting
infor ation).
Diamide conju ates in which the two d -ruthenium units are onnected through succinic,
malonic an glutaric li kers could not be btained, either using the respective bis-acyl chlorides or
the corresponding dicarboxylic acids. Degradation of the malonyl chloride reagent was observed in
the used reaction conditions. In the cases of the succinyl and glutaryl chlorides, the high reactivity of
the di-ruthenium amine 4 favored the formation of the corresponding 5 and 6 atom cyclic amide side
products with the 1-pyrrolidine-2,5-dione and 1-piperidine-2,6-dione rings.
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The diester 15–16 and diamide 17–18 conjugates with aromatic linkers were recovered with 32%,
82%, 50%, and 21% yield, respectively using similar conditions, by the reaction of two equivalents
of di-ruthenium hydroxy 3 or amino intermediate 4 with commercially available meta and para
substituted bis-acyl chloride compounds in basic conditions (TEA) at low temperature (0 ◦C) under
inert atmosphere (Scheme 4).
For the obtainment of conjugate 20 containing three thiolato-bridged dinuclear ruthenium(II)-arene
units in a linear ‘beads-on-a-string’ distribution (Figure S1), two types of ruthenium intermediates
were necessary: (i) compound 3 containing one free hydroxy group used for the two capping units,
and (ii) the dihydroxy compound 5 (Scheme 1) playing the role of core for connecting two units of 3
via appropriately difunctionalized linkers. Two strategies were considered for the synthesis of this
type of conjugates with three di-ruthenium units in a linear arrangement. In one approach, the linkers
were anchored on the central dinuclear ruthenium unit in a first step followed by the attachment of the
remaining two dinuclear units in a second step. Alternatively, the order of the reactions was reversed,
thus first the linkers were reacted with the ‘cap’ ruthenium dinuclear units followed by the connection
on the central dinuclear ruthenium moiety. A two-step synthetic pathway was used (Schemes 5 and 6).
First, a glutaric acid linker was attached to the mono-hydroxy di-ruthenium intermediate 3 with
the formation of precursor 19 presenting a free carboxylic acid group (Scheme 5). Compound 19
was obtained in 96% yield, by reacting 3 with glutaric anhydride in basic conditions (TEA) at low
temperature (0 ◦C) under inert atmosphere (N2).
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tris(2-hydroxyet l)amine, and, respectively, 1,3,5-benzenetrimethanol, following the reactions
presented in Scheme 6.
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The amide coupling of the core linkers 21 and 22 with mixed amino trithiolato-bridged dinuclear
ruthenium(II)-p-cymene compound 4 afforded the star-like compounds 23 and 24 (Scheme 7).
The reactions were performed in the presence of coupling agents EDCI and HOBt, in basic conditions
(DIPEA), under inert atmosphere (N2) at room temperature (Scheme 7).
All compounds were characterized by 1H and 13C NMR spectroscopy, mass spectrometry and
elemental analysis (see Materials and Methods—Chemistry secti in Supporting information for
full d tails). For die ter alkyl linker conjugates 6–10, ester bond f rmation led t important shifts of
the resonanc s corresponding to the aromatic protons in α and β position to the former OH group,
respectively with ∆δH ≈ 0.12 ppm highfield, and ∆δH ≈ 0.41 ppm lowfield. Likewise, the aromatic
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protons of the p-cymene rings were lowfield shifted with about ∆δH ≈ 0.05–0.26 ppm, and the resonance
of the aromatic carbon connected to the ester group (C-O-(C=O)) shifted from 160 ppm to 151 ppm.
Similarly, the formation of the amide bond in alkyl connected conjugates 11–14 was associated
with important shifts of specific resonances in the 1H-NMR spectra, which facilitated the monitoring
of the reactions’ evolution. The resonance corresponding to the amide hydrogen atom (NH-(C=O))
appeared at around 11 ppm. Amide bond formation led to important shifts of the resonances
corresponding to the aromatic protons in α and β position to the former NH2 group, respectively with
∆δH ≈ 1.36 ppm lowfield, and ∆δH ≈ 0.23 ppm lowfield. Compared to the case of the diester conjugates
6-10, the resonances corresponding to the aromatic protons of the p-cymene rings were less affected
(lowfield shift ∆δH = 0.01–0.02 ppm). In conjugates 11–14, the resonance of the aromatic carbon
connected to the amide group (C-NH-(C=O)) shifts from 149 ppm to 130 ppm.
In the diester (15, 16) and diamide (17, 18) conjugates with aromatic linkers, the resonance of the
aromatic protons in α and β position to the newly formed ester or amide group also shifts compared to
corresponding hydroxy and amine di-ruthenium intermediates 3 and 4. Ester bond formation in 15
and 16 led to shifts of the resonances corresponding to the aromatic protons in α and β position to
the former OH group, with ∆δH ≈ 0.02 ppm lowfield and, respectively, with ∆δH ≈ 0.51 ppm lowfield.
Amide bond formation in 17 and 18 led to shifts of the resonances corresponding to the aromatic
protons in α and β position to the former NH2 group, respectively with ∆δH ≈ 1.48 ppm lowfield,
and ∆δH ≈ 0.31 ppm lowfield. Nevertheless, the nature of the linker (aliphatic vs. aromatic) had less
influence on the NMR resonances compared to the type of bond (ester vs. amide). On the other hand,
the resonances of the aromatic carbon connected to the heteroatom of the ester and amide groups
(C-X-(C=O)) shifted highfield with ∆δC ≈ 9 ppm for the esters and ∆δC ≈ 18 ppm for the amides.
For 20, the tricationic conjugate in which the di-ruthenium units are distributed in a linear
arrangement, two sets of resonances could be easily identified corresponding to the two types of
thiolato-bridged dinuclear ruthenium(II)-p-cymene moieties positioned as core or on the end of
the side-arms.
The formation of compound 23 was evidenced by important lowfield shifts of the resonances
corresponding to the aromatic protons in α and β position to the amide (NH-(C=O)) of ∆δH = 1.31 ppm
and ∆δH = 0.15 ppm, respectively. For the respective carbon atoms in the 13C-NMR spectrum of 23
a shift toward low field of ∆δC = 4.7 ppm and highfield of ∆δC = 0.8 ppm of the aromatic carbons
in α and respectively β position to the amide (NH-(C=O)) was observed. In addition, an important
highfield shift (∆δC = 19 ppm) of the aromatic quaternary carbon connected to the nitrogen was also
noticed. A similar effect was also observed in the 1H-NMR and 13C-NMR spectra of triamide 24.
Electrospray ionization mass spectrometry (ESI-MS) corroborated the spectroscopic data with
the intermediates 3–5 with one di-ruthenium unit exhibiting molecular ion peaks corresponding to
[M-Cl]+ ions, conjugates 6–18 with two di-ruthenium unit as [M-2Cl]2+ ions, and linear and tripodal
conjugates 20, 23, and 24 with three di-ruthenium units as [M-3Cl]3+ ions.
Intermediate complexes 3 and 4 as well as newly obtained polynuclear conjugates 6–18 and
20–22 were stable in DMSO-d6 at 0 ◦C. (Supplementary Figures S4−S8). Of note, two new very small
resonances emerged at ~5.8 and ~8.4 ppm in some spectra recorded after 30 days (for instance for
15). Yet, although the exact origin of these resonances and the compound(s) they characterize remain
unknown, they do not denote a sign of decomposition or formation of a new complex, otherwise new
resonances would have appeared in the aromatic region and in the p-cymene region around 5.5 ppm
and between 0.5 and 3 ppm. Very importantly, recent studies by some of us have shown that dinuclear
arene ruthenium complexes are inert to ligand substitutions and remain stable for long period in water
solutions or in organic solvents [55–58].
2.2. In Vitro Activity against the Apicomplexan Parasite Toxoplasma gondii
The new conjugates presented in this study were investigated to assess the impact of compound
exposure upon T. gondii β-gal grown in HFF and non-infected HFF. Cultures exposed to concentrations
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of 1 and 0.1 µM of each compound of interest (e.g., hydroxy and amino trithiolato-bridged dinuclear
ruthenium(II)-arene complexes 3–5, the conjugates with two di-ruthenium units and various types of
linkers 6–18, and the conjugates with three di-ruthenium units and different architectures 20, 23, and 24,
Supplementary Table S1 and Figure 4). The results obtained for two other compounds, acetyl ester
25 and amide 26 [104] (see structures in Supporting information) are also presented for comparison.
As a measure of parasite proliferation, β-galactosidase activity was determined, while the impact on
non-infected HFF was assessed using the AlamarBlue assay.
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Figure 4. Clustered column chart showing the in vitro activities at 1 (A) and 0.1 (B) µM of the
21 compounds on HFF viability and T. gondii β-gal proliferation. Non-infected HFF monolayers treated
only with 0.1% DMSO exhibited 100% viability and 100% proliferation was attributed to T. gondii β-gal
tachyzoites treated with 0.1% DMSO only. For each assay, standard deviations were calculated from
triplicates. Data for compounds 3, 4 and 5 were previously reported [66] and data for 25 and 26 are
part of another study [104].
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Compound 5, possessing two polar hydroxy groups, inhibited T. gondii β-gal tachyzoite
proliferation more effectively compared to compounds 3 and 4 possessing only one OH or NH2
group. Acetyl ester 25 and acetyl amide 26 were also more active against the parasite compared to
free OH and NH2 analogues 3 and 4, indicating that the increase in hydrophobicity appears to favor
antiparasitic activity. However, 26 is also more cytotoxic against HFF host cells.
In the series of the compounds with two di-ruthenium units and diester alkyl connectors,
the derivatives with medium long chain 7 and 8 (n = 3 or 4) were active against T. gondii β-gal
tachyzoites but also exhibited increased toxicity against HFF host cells. From this first screening,
the most interesting analogue with an alkyl diester linker was compound 9 (n = 5). Diester compounds
6 and 9 were more efficient against T. gondii β-gal tachyzoites compared to the hydroxy di-ruthenium
compound 3 and exhibited a rather close activity/toxicity profile to acetyl compound 25.
The diamide derivatives 11–14, with two di-ruthenium units and alkyl linkers, were less cytotoxic
in HFF host cells, but displayed also reduced activity with respect to T. gondii tachyzoite inhibition
compared to the diester compounds 6–10. Derivatives 11–14 were also less cytotoxic and less efficacious
against T. gondii than the acetyl amide 26 or the amino di-ruthenium compound 4. In this small alkyl
diamide set of conjugates, increasing the length of the spacer between the two di-ruthenium units had
a favorable effect on the antiparasitic activity.
Interestingly, a similar structural effect (namely amide compounds less active against T. gondii/less
cytotoxic for HFF) when compared to ester analogues, could be observed in the case of the derivatives
15–18 presenting two di-ruthenium units and aryl connectors. Thus, diester compounds 15 and 16 were
significantly more active against T. gondii tachyzoites compared to their respective diamide analogues
17 and 18. This might be the consequence of the more important conjugation of the amide bond
compared to the ester bond, which can lead to increased rigidity of the molecule, or to the difference of
chemical stability of the ester and amide bonds in the cellular environment.
Compound 20 with three di-ruthenium units in a linear distribution displayed an increased
activity against T. gondii β-gal compared to the two star-shape compounds 23 and 24 but was also
more cytotoxic in HFFs. Similar to the di-hydroxy analogue 5 and the acetyl ester 25, compound 20
showed increased activity against the parasite than the mono-hydroxy di-ruthenium compound 3.
It is important to note that in compound 20 the three di-ruthenium units were connected exclusively
through ester bonds, while in compounds 23 and 24 the three units were connected to the central core
through amide bonds. The increased molecular volume and rigidity might be responsible for the poor
antiparasitic properties of compounds 23 and 24.
Based on this preliminary screening, twelve compounds exhibiting favorable antiparasitic activity
and low or intermediate impairment of HFF viability were selected for the determination of the IC50
values in T. gondii β-gal and assessment of HFF viability after exposure to 2.5 µM. To determine the
IC50 value of a compound, two criteria had to be simultaneously satisfied: (i) T. gondii β-gal growth
was inhibited by 90% or more compared to an untreated control when the compound was applied at
1 µM, and (ii) HFF host cell viability was not impaired by more than 50% for a compound applied
at 1 µM. Pyrimethamine, currently used for the treatment of toxoplasmosis, and which inhibited the
proliferation of T. gondii β-gal tachyzoites with an IC50 value of 0.326 µM and did not affect HFF
viability at 2.5 µM (Table 1), was used as reference compound. The results are summarized in Table 1,
and dose response curves are shown in Supplementary Figure S3. The selection included the three
intermediate compounds 3, 4, and 5 containing one di-ruthenium unit and free OH or NH2 groups,
along with three alkyl diester compounds 6, 8, and 9, the two aryl diester compounds 15 and 16, as well
as compound 20 presenting three di-ruthenium units in a linear arrangement.
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Table 1. Half maximal inhibitory concentration (IC50) values (µM) on T. gondii β-gal for twelve selected
compounds and pyrimethamine (used as standard), and their effect at 2.5 µM on HFF viability.
Compound T. gondii β-gal HFF
IC50 (µM) [LS; LI] c SE d Viability at 2.5 µM (%) e SD f
Pyrimethamine a 0.326 [0.288; 0.396] 0.051 99 6
Compounds with one trithiolato-bridged ruthenium(II)-p-cymene unit
3 a 0.117 [0.098; 0.139] 0.051 56 6
4 a 0.153 [0.127; 0.185] 0.049 51 5
5 a 0.115 [0.098; 0.135] 0.045 2 4
25 b 0.065 [0.042; 0.101] 0.092 16 5
Compounds with two trithiolato-bridged ruthenium(II)-p-cymene units and alkyl diester linkers
6 0.060 [0.045; 0.080] 0.076 0 0
9 0.159 [0.139; 0.183] 0.064 50 1
10 0.123 [0.088; 0.172] 0.084 27 1
Compounds with two trithiolato-bridged ruthenium(II)-p-cymene units and alkyl diamide linkers
12 0.397 [0.315; 0.501] 0.072 65 1
13 0.531 [0.491; 0.575] 0.019 74 1
Compounds with two trithiolato-bridged ruthenium(II)-p-cymene units and meta and para substituted diester linkers
15 0.373 [0.342; 0.407] 0.034 49 1
16 0.185 [0.167; 0.204] 0.032 53 1
Compounds with three trithiolato-bridged ruthenium(II)-p-cymene units in a star-shape arrangement
24 0.033 [0.014; 0.076] 0.178 55 1
a Data for pyrimethamine, 3, 4 and 5 were previously reported [66]. b Data for 25 are part of another study [104].
c Values at 95% confidence interval (CI); LS is the upper limit of CI and LI is the lower limit of CI. d The standard
error of the regression (SE), represents the average distance that the observed values fall from the regression line.
e Control HFF cells treated only with 0.25% DMSO exhibited 100% viability. f The standard deviation of the mean
(six replicate experiments).
Interestingly, the more rigid and sterically hindered aryl diester analogues 15 and 16 were less
active in inhibiting T. gondii tachyzoite proliferation compared to the alkyl diester compounds 6, 9 and
10, and they were also less cytotoxic for HFF at 2.5 µM. Compound 24 with three di-ruthenium units
exhibited the highest antiparasitic activity, but was also highly cytotoxic in HFF. Mono- and di-hydroxy
compounds 3 and 5 had slightly lower IC50 values compared to the amino compound 4.
The flexibility of the compounds and the molecular volume seemed to have an important impact
on the measured IC50 values against the apicomplexan parasite T. gondii, while the global charge
appeared to influence the biological activity to a lesser extent.
2.3. In Vitro Anticancer Activity
The cytotoxicity of the di-ruthenium hydroxy and amino intermediates 3–5, of the conjugates with
two trithiolato-bridged dinuclear ruthenium(II)-p-cymene complexes linked with alkyl diester (6, 7,
and 9), alkyl diamide (11–13), or aryl linkers (15, 17, 18), and of the conjugates with three di-ruthenium
units 20 and 24 was assessed in the human embryonic kidney cell line HEK293 used as a model for
non-cancer cells, in the human ovarian carcinoma cell lines A2780 and A2780cisR, with the latter
exhibiting acquired resistance to cisplatin, and in two cell lines A24 and (D-)A24cisPt8.0 that originate
from human lung adenocarcinoma (Supplementary Table S2, Figures 5 and 6). The A24 cells and its
subline (D-)A24cisPt8.0 were described previously [105]. The (D-)A24cisPt8.0 subline is approximately
30-fold more resistant to cisplatin (cisPt) compared to the A24 cells [105]. The cytotoxicity values of
cisplatin (cisPt), used as control, are also presented.
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Figure 6. Comparison of the IC50 values (µM, 72 h) determined for cisplatin (cisPt) and selected
trithiolato-bridged dinuclear ruthenium(II)-p-cymene compounds toward human lung adenocarcinoma
wild type A24 and de-induced (D-)A24cisPt8.0 subline cells and human embryonic kidney HEK293 cells.
Apart from compounds 17 and 18 assessed in A2780 human ovarian cells, all ruthenium compounds
were more cytotoxic than cisplatin on all cell lines tested in this study (Figure 5 and Table S2). In terms of
selectivity, compounds 3–5 and 11 assessed in cancer cells showed only very reduced selectivity to the
non-cancer HEK293 cells. Nevertheless, hydroxy and amine compounds with only one di-ruthenium
unit (3–5) and ester bonded conjugates (6, 7, 9, 15, and 20) present similar cytotoxicity against A2780 and
A2780cisR human ovarian cells, and A24 and (D-)A24cisPt8.0 human lung adenocarcinoma cells,
irrespectively of the cisplatin resistance profile of the cell lines. This is indicative for a possible different
mechanism of action compared to cisplatin, and the potential to circumvent cisplatin cross-resistance.
Compounds 3 and 4, containing only one polar OH and NH2 group, respectively, were less cytotoxic
on all tested cell lines compared to compound 5 presenting two hydroxy groups.
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Irrespective of the nature of the connectors (alkyl or aryl) or of the number of di-ruthenium
units (two or three), conjugates with ester bonds presented rather similar antiproliferative profiles,
namely they were more cytotoxic compared to conjugates in which the di-ruthenium units were
anchored via amide bonds (11–13, 17, 18, and 22).
Diester compounds 6, 7, and 9, containing two di-ruthenium units and alkyl connectors,
were among the most cytotoxic derivatives of the series in all tested cell lines. No or very little selectivity
against cancer cells compared to HEK293 cells could be observed for 6, 7, and 9. These compounds
appeared to be slightly more cytotoxic on the human lung adenocarcinoma A24 and (D-)A24cisPt8.0 cell
lines, compared to the human ovarian cancer cells A2780 and A2780cisR. Almost no influence of the
linker length was observed for these conjugates with alkyl diester connectors.
Compounds 11, 12, and 13 were less active in the cisplatin resistant cell lines A2780cisR and
(D-)A24cisPt8.0 compared to A2780 and A24 cell lines. If these compounds with alkyl diamide linkers
were more cytotoxic then cisplatin, they presented lower antiproliferative activities compared to
conjugates with alkyl diester connectors 6, 7, and 9. The length increase of the diamide connector was
associated with a decrease in cytotoxicity against all tested cancer cells, and this effect was stronger in
cisplatin resistant cancer cells A2780 and (D-)A24cisPt8.0.
A difference was perceived between the ester 15 and amide compounds 17 and 18 with two
di-ruthenium units and aromatic connectors, the first one being significantly more cytotoxic on all
tested cell lines. Thus, diester compound 15 remained among the most cytotoxic of the series in all cell
lines (IC50 values between 0.036 to 0.094 µM). Diamide compounds 17 and 18 were equally cytotoxic in
HEK293 and A2780 cells but were less cytotoxic in the cisplatin resistant A2780cisR cells. Nevertheless,
the cytotoxicity profile of human lung adenocarcinoma A24 and (D-)A24cisPt8.0 cancer cells was
different from human ovarian cancer cells A2780 and A2780cisR. No important difference was observed
between conjugates 6, 7, and 9 with alkyl and 15 with aryl diester linkers. The variations were more
important in the case of alkyl 11–13 and aryl 17, 18 diamide connected conjugates, especially regarding
the antiproliferative activity in the human ovarian cancer cells A2780 and A2780cisR.
Interestingly, noticeable differences in activity could be observed between compounds containing
three di-ruthenium units. While compound 20 (with a linear distribution of the three complexes)
remains among the most cytotoxic of the series (IC50 values ranging between 0.033 and 0.074 µM),
the tripodal compound 24 was less cytotoxic (IC50 values of 0.167 to 0.277 µM). Whereas in conjugate
20 the three di-ruthenium units are connected via ester bonds, they are anchored to the central core
through amide bonds in compound 24. No important differences in cytotoxicity levels were found in
all cancer cells and in HEK293 cells.
Cytotoxicity is a multifactorial process, and resistance to platinum compounds in the A2870cisR
cell line is attributed amongst others to decreased uptake, increased glutathione and glutathione
S-transferase levels, and increased DNA repair (adduct removal). Uptake may be correlated with
Ctr1 transporter expression, which is expressed at lower levels in cisplatin resistant A2870cisR cells
compared to sensitive cell lines [106–108].
3. Materials and Methods
3.1. Chemistry
The materials and methods corresponding to the chemistry part are presented with full details in
the ‘Materials and methods—Chemistry’ section in Supporting information.
3.2. In Vitro Activity Assessment against T. gondii Tachyzoites and HFF
If not otherwise stated, all tissue culture media were purchased from Gibco-BRL, and biochemical
agents purchased from Sigma-Aldrich. HFF (SCRC-1041.1) were purchased from ATCC, and were
maintained in DMEM medium containing 10% fetal calf serum (FCS, Gibco-BRL, Waltham, MA, USA),
and antibiotics as described [109]. Transgenic T. gondii β-gal (expressing the β-galactosidase gene from
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Escherichia coli) [110] were kindly provided by Prof. David Sibley (Washington University, St. Louis,
MO, USA) and were maintained in HFF as host cells, and were isolated as described before [109].
Compounds were prepared as 1 mM stock solutions in DMSO (dimethyl sulfoxide, Sigma,
St. Louis, MO, USA). For activity assays, HFF monolayers were cultured in 96 well plates by seeding
5 × 103 HFF per well and allowing them to grow to confluence in phenol-red free culture medium
at 37 ◦C/5% CO2. For infection, T. gondii β-gal tachyzoites were separated from their host cells as
described [109], parasites were isolated and HFF monolayers were infected with freshly isolated
tachyzoites (1 × 103 per well), with compounds solutions added concomitantly during infection.
For the primary screening, T. gondii β-gal infected HFF were exposed to 0.1 and 1µM of each
compound for a period of 72 h, or the corresponding concentration of DMSO (0.01% and 0.1%,
respectively) as control. For the determination of IC50 values against T. gondii β-gal, compounds were
added at 8 concentrations: 0.007, 0.01, 0.03, 0.06, 0.12, 0.25, 0.5, and 1 µM. After 72 h of culture
at 37 ◦C/5% CO2, the medium was aspirated, and cells were permeabilized by adding 90 µL PBS
(phosphate buffered saline) containing 0.05% Triton X-100. After addition of 10 µL 5 mM chlorophenol
red-β-D-galactopyranoside (CPRG; Roche Diagnostics, Rotkreuz, Switzerland) dissolved in PBS,
the absorption shift was measured at 570 nm wavelength at various time points using an EnSpire®
multimode plate reader (PerkinElmer, Inc, Waltham, MA, USA). For the primary screening at 0.1 and
1 µM, the activity, measured as the release of chlorophenol red over time, was calculated as percentage
from the respective DMSO control, which represented 100% of T. gondii β-gal growth. For the
IC50 assays, the activity measured as the release of chlorophenol red over time was proportional to
the number of live parasites down to 50 per well as determined in pilot assays. IC50 values were
calculated after the logit-log-transformation of relative growth and subsequent regression analysis.
All calculations were performed using the corresponding software tool contained in the Excel software
package (Microsoft, Redmond, WA, USA).
Cytotoxicity assays using uninfected confluent HFF host cells were performed as previously
described [111] by AlamarBlue assay. In brief, confluent HFF monolayers in 96 well-plates were
exposed to 0.1, 1 and 2.5 µM of each compound. Non-treated HFF as well as DMSO controls (0.01%,
0.1% and 0.25%) were included. After 72 h of incubation at 37 ◦C/5% CO2, the medium was removed,
and plates were washed once with PBS. Resazurin stock solution was diluted 1:200 in PBS and 200 µL
were added to each well. Plates were read at excitation wavelength 530 nm and emission wavelength
590 nM at the EnSpire® multimode plate reader (PerkinElmer, Inc). Fluorescence was measured at
different timepoints. Relative fluorescence units were calculated from timepoints with linear increase.
3.3. In Vitro Anticancer Activity
Human ovarian carcinoma cells A2780 and the cisPt resistant variant A2780cisR were purchased
from the European Center of Cell Cultures (ECACC, Salisbury, UK). The HEK-293 cell line was kindly
provided by Prof. Mühlemann, University of Bern. The A24 cells and its subline (D-)A24cisPt8.0 were
described previously [105]. The cancer cells A24 and (D-)A24cisPt8.0 [105] (human lung adenocarcinoma
cells wild type A24 and cisPt resistant (D-)A24cisPt8.0 subline), A2780 and A2780cisR (human ovarian
cisplatin sensitive and resistant cancer cells), together with HEK293 (human embryonic kidney)
cells as model for normal cells, were included in the study for the evaluation of the ruthenium
compounds’ selectivity and cross-resistance with cisplatin. The A24 sublines, A2780 and A2780cisR
were cultured in RPMI 1640 medium without riboflavin, phenol red and antibiotics, buffered with
4.5 mM HEPES (BioConcept, Allschwil, Switzerland), supplemented with 10% (v/v) fetal bovine serum
(FBS) (Thermo Scientific, Weltham, MA, USA) as the only source of flavins, and with 13.5 mM NaHCO3.
In order to retain cisplatin resistance in the A2780cisR cell line, 1 µM cisplatin was added to the medium
every 2–3 passages. HEK293 cells were cultured in DMEM/F12 medium, supplemented with 10%
(v/v) FBS. At subcultivation, cell monolayers were rinsed with PBS and exposed for 3 min to StemPro
Accutase Cell Dissociation Reagent (Thermo Scientific, Weltham, MA, USA) at 36.5 ◦C. Detached cells
were resuspended in culture medium. Cell densities were determined using Moxi flow cytometer
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according to manufacturer instructions (Orflo Technologies, Ketchum, ID, USA). Experiments and
subcultivations were performed using light with wavelengths above 520 nm to prevent photochemical
artifacts. Cytostatic drug response was quantified as previously reported [105]. Briefly, HEK293, A24,
A2780, A2780cisR, and (D-)A24cisPt8.0 single cell suspensions were freshly prepared from confluent
cell layers using Accutase and diluted in culture medium to a cell density of 2 × 104 or 8 × 104 cells/mL
(D-)A24cisPt8.0. 150 µl of this suspension was combined with 150 µl of twice the cisPt or Ru-compound
concentration in a 96-well microtiter plate (TPP, Trasadingen, Switzerland). Test plates were incubated
under standard conditions for 72 h. Cell densities were determined in a Casy I cell analyzer using
Casystat software (OLS OMNI Life Science, Bremen, Germany). Drug concentrations leading to 50%
growth inhibition compared to controls were calculated using GraphPad Software (La Jolla, CA, USA).
Each experiment was done in triplicates.
4. Conclusions
The polynuclear organometallic approach was pioneered by the inorganic trinuclear platinum
compound BBR 3464. The aim of this study was to extend and apply this concept to new conjugates
containing two or three trithiolato-bridged ruthenium(II)-arene units and to assess the biological
activity of the new compounds. We synthesized a library of 16 new compounds containing two and
three di-ruthenium moieties as well as the corresponding 3 trithiolato di-ruthenium(II)-p-cymene
intermediates and evaluated the activities of these compounds against T. gondii tachyzoites and cancer
cells in vitro.
Remarkably, the in vitro activity assessment against T. gondii tachyzoites grown in HFF led to seven
compounds (three with one, three with two, and one with three di-ruthenium units), which displayed
lower IC50 values than the standard drug pyrimethamine. However, the IC50 values show that the
compounds with two or three trithiolato di-ruthenium(II)arene units do not appear more promising
than the intermediates 3–5 with only one di-nuclear unit. Of note, the more rigid and sterically
hindered aryl diester analogues 15 and 16 with two trithiolato di-ruthenium units are less active against
T. gondii β-gal and less toxic for HFF host cells compared to the alkyl diester derivatives 6 and 8–9.
This insight could be used for further refinement of the structures to improve the activity against
T. gondii. From these results we conclude that the molecular flexibility and volume of the compounds
have an important impact on the measured IC50 values against T. gondii, while the global positive
charge of the compounds influences the biological activity to a lesser extent.
We also determined the cytotoxicity of 14 selected compounds against the cell lines HEK293,
A2780, A24, A2780cisR, and (D-)A24cisPt8.0, which resulted in IC50 values ranging from 23 to 650 nM.
Remarkably, all tested compounds were considerably more cytotoxic than cisplatin in A2780cisR,
A24 and de-induced (D-)A24cisPt8.0 subline cancer cells. Compounds 3–9, 11, 15, and 20 presented
IC50 values more than two orders of magnitude lower than those measured for cisplatin against
(D-)A24cisPt8.0 cells. Interestingly, irrespective of the nature of the connectors (alkyl or aryl) or of
the number or di-ruthenium units (two or three), the conjugates with ester bonds exhibited similar
antiproliferative profile, and were more cytotoxic than the conjugates in which the di-ruthenium
units were linked via amide bonds. Compounds 3–5 with one and 11 with two di-ruthenium units
showed a moderate selectivity for the tested cancer cells, and they could be exploited to design
new derivatives for future studies. The compounds with two and three di-ruthenium units do not
seem more advantageous compared to the intermediate complexes with only one di-nuclear unit 3–5.
Nevertheless, the results suggest the potential to circumvent cisplatin cross-resistance.
Overall, this study shows that the concept of extended multinuclearity applied to di-nuclear
trithiolato-bridged ruthenium (II)-p-cymene compounds is worth additional assessment.
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